Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Center for Drug Development

Neither a doctor nor a teaching hospital

Research payments

$22,568,015

3,421 payments

Through program year 2025, Texas Center for Drug Development is reported as receiving $22,568,015 in research payments, across 3,421 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $500,305 90
2024 Research $253,826 85
2023 Research $958,505 543
2022 Research $14,606,964 2,313
2021 Research $5,510,032 219
2020 Research $314,054 103
2019 Research $424,328 68

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $20,014,622 2,878 payments
  2. GlaxoSmithKline, LLC. $1,169,087 152 payments
  3. Merck Sharp & Dohme Corporation $814,555 96 payments
  4. Sanofi Pasteur Inc. $192,497 50 payments
  5. Pfizer Inc. $163,627 11 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $66,319 16 payments
  7. Bavarian Nordic A/S $66,151 59 payments
  8. Biohaven Pharmaceuticals, Inc. $19,343 3 payments
  9. AbbVie, Inc. $15,500 4 payments
  10. Vanda Pharmaceuticals Inc. $13,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $6,311,941 350 payments
  2. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $5,065,871 140 payments
  3. A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants $3,299,270 109 payments
  4. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $2,930,571 57 payments
  5. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $733,542 1,353 payments
  6. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $596,962 33 payments
  7. V503-049 A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age $430,553 31 payments
  8. Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults $400,356 274 payments
  9. An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years $332,699 8 payments
  10. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $312,151 25 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record